Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET) Abstract #904

Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Aim(s): To determine the role of Met on RFS in NET patients (pts).
Materials and methods: A retrospective analysis was conducted comparing NET pts with recent diagnosis (< 1 yr) of diabetes mellitus, with HbA1c≤7%, treated with Met (group A) to non-diabetic NET pts without Met (group B) with comparable clinical and pathological characteristics. RFS was evaluated by Kaplan-Meier analysis
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello

To read results and conclusion, please login ...

Further abstracts you may be interested in

#724 Contrast-Enhanced Ultrasonography (CEUS) Reliably Predicts Tumor Progression in Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) exhibit a typical vascular pattern in the arterial phase on CEUS. The role of CEUS in the prognostic evaluation of pancreatic NET (pNET) has been poorly investigated.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Michela Del Prete
#540 Diagnositc and Prognostic Role of 68GA-DOTATATE PET in Patients with Neuroendocrine Tumors
Introduction: Octreoscan (OS) is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR Francesca Marciello
#1452 Prognosis of Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Tumor Slope is Prognostic Together with Tumor Burden and Grade
Introduction: Currently, no prognostic stratification exists in stage IV pNET patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#806 Long-Term Prognosis of Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Disease
Introduction: Management of pancreatic neuroendocrine tumours (PNET) associated with von Hippel-Lindau (VHL) disease is challenging because of their malignant potential and poorly predictable prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Louis De Mestier